Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme.
about
NSC666715 and Its Analogs Inhibit Strand-Displacement Activity of DNA Polymerase β and Potentiate Temozolomide-Induced DNA Damage, Senescence and Apoptosis in Colorectal Cancer CellsSupportive management of patients with brain tumors.The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.Novel drugs in pediatric gliomas.Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant gliomaOdds of death after glioblastoma diagnosis in the United States by chemotherapeutic era.Mesenchymal migration as a therapeutic target in glioblastoma.Surgical resection of malignant gliomas-role in optimizing patient outcome.Hospitalization burden and survival among older glioblastoma patients.Alkylation sensitivity screens reveal a conserved cross-species functionome.Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registriesPeptide-Targeted Gold Nanoparticles for Photodynamic Therapy of Brain Cancer.Theranostic 3-Dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma.Cytotoxic and molecular chemotherapy for high-grade glioma: an emerging strategy for the future.Suppression of the invasive potential of Glioblastoma cells by mTOR inhibitors involves modulation of NFκB and PKC-α signaling.Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced deliveryEffective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cellsAspergillosis in a patient receiving temozolomide for the treatment of glioblastoma.Noninvasive imaging of apoptosis and its application in cancer therapeutics.Central diabetes insipidus: a previously unreported side effect of temozolomide.The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United StatesTime trends in glioblastoma multiforme survival: the role of temozolomide.Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).Temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: a systematic review.Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study.Management of patients with newly diagnosed malignant primary brain tumors with a focus on the evolving role of temozolomide.Biomaterial-Based Implantable Devices for Cancer Therapy.Harnessing nanomedicine for therapeutic intervention in glioblastoma.Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma.Prognostic and predictive value of p53 in low MGMT expressing glioblastoma treated with surgery, radiation and adjuvant temozolomide chemotherapy.The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells.Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.Two cases of cutaneous drug eruption associated with temozolomide therapy for glioblastoma.The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma.Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice.BICD1 expression, as a potential biomarker for prognosis and predicting response to therapy in patients with glioblastomas.Sensitization of glioma cells by X-linked inhibitor of apoptosis protein knockdown.Hepatic encephalopathy after treatment with temozolomide.
P2860
Q28546932-5FAB1BE3-A3DA-46FD-B33D-AA942A29792EQ30444752-0BD87091-1E7A-4149-982F-2FB3FB0F2E9EQ33578787-A18D5296-228E-490F-9B4B-478E7637D0A7Q33685551-83FB3E11-6FDF-43E1-AC2F-41AED545F6F0Q33696343-0DEB0737-9705-4BE1-8728-2E32C73AB519Q33913598-D9A1E908-FE4A-4711-8EE4-1984A1E896F2Q34002994-BEF3B598-573F-45C6-A802-3B1EB34A8CB3Q34324963-2A13C368-1FD7-435D-B788-E59A1DAB88C3Q34359639-F829E8CA-174E-478F-93AA-A8A55A125664Q34434871-B99B68E8-80E0-454A-8ADE-E4EF22E6C981Q35605776-5A74EC34-0635-43E9-9B62-8F96B7B595B6Q35624110-1C9A2837-45A0-4C4B-A0F8-AB8472EAD327Q36297929-387B1F4C-4AAB-45F8-AF82-9DA4BCFBD6F0Q36429731-D2AA5BB1-A8E9-41F8-A01E-631D0516A7EFQ36650919-166A2DB4-C043-4570-9801-5E7A36D69A9FQ36990672-E0DEE03F-9F41-4942-BC23-CFFBBF5AB072Q37091154-430C7CD0-63E8-4D1E-8CBF-880836C702A4Q37151373-B6C3A2E2-3B70-4434-9E19-2D51A6FF3363Q37156573-2A2295DD-C25C-4850-8FF9-E3659887AFB0Q37215472-CB6C1E90-2E27-456B-A275-F536F9817359Q37268867-B8C1CABB-D66A-45FC-B566-AFFE59CA6025Q37312701-299D51B1-37EA-4AB8-BFD6-DB8B74D7FC1CQ37329315-0A66A7F4-35A4-42C5-86D8-4D48182C9959Q38170398-5F4E3615-4970-461A-A476-A9D830F0A66DQ38401201-755B258C-CEDF-4106-8577-A3236629D515Q38535943-D3E18A8F-6195-4D5A-B284-CF1FD9EB949DQ38790816-241F70DA-E1CD-49A4-B970-3D870A57CD3BQ38862946-B3B70C39-77CA-4B64-A5E4-773E3DD58359Q39060215-161D833B-7037-4F54-9575-73BC1A7E3403Q39952790-014D5085-CBB1-48B4-900E-87983348C613Q41484860-3BAD73EA-AD20-4111-A471-F6157B7A4B56Q42274901-4A011426-AA41-4565-AF96-11DB026924A5Q43056413-FDF3E260-9E0F-4D42-BAA2-71FAC6D425F8Q43953167-DF308C57-80DE-4466-8324-9D95632C27B8Q45298561-B31AE2F3-7DB6-4A74-8B19-E599EB9E30ACQ48240742-01EE3A50-2EB4-4895-B6AC-A015C4E7B5E6Q49640790-274AC967-0F22-4A71-8A23-A3BE22963D9AQ53159288-CACCEBD2-33AE-43C8-AD2E-A0B1E6B6E6CFQ55463913-FDE34CBF-146C-41ED-8532-3920530D6468
P2860
Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Food and Drug Administration D ...... nosed glioblastoma multiforme.
@ast
Food and Drug Administration D ...... nosed glioblastoma multiforme.
@en
type
label
Food and Drug Administration D ...... nosed glioblastoma multiforme.
@ast
Food and Drug Administration D ...... nosed glioblastoma multiforme.
@en
prefLabel
Food and Drug Administration D ...... nosed glioblastoma multiforme.
@ast
Food and Drug Administration D ...... nosed glioblastoma multiforme.
@en
P2093
P1476
Food and Drug Administration D ...... nosed glioblastoma multiforme.
@en
P2093
John R Johnson
Martin H Cohen
Richard Pazdur
P304
P356
10.1158/1078-0432.CCR-05-0722
P407
P433
P577
2005-10-01T00:00:00Z